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Clinical Significance of a Large Difference (≥ 2 points) between 
Biopsy and Post-prostatectomy Pathological Gleason Scores  
in Patients with Prostate Cancer
We investigated the clinical significance of large difference (≥ 2 points) between 
biopsy-derived (bGS) and post-prostatectomy Gleason scores (pGS). At 14 medical 
centers in Korea, 1,582 men who underwent radical prostatectomy for prostate 
cancer were included. According to the difference between bGS and pGS, the patients 
were divided into three groups: A (decreased in pGS ≥ 2, n = 30), B (changed in pGS 
≤ 1, n = 1,361; control group), and C (increased in pGS ≥ 2, n = 55). We evaluated 
various clinicopathological factors of prostate cancer and hazards for biochemical 
failure. Group A showed significantly higher mean maximal percentage of cancer in 
the positive cores (max%) and pathological T stage than control. In group C, the 
number of biopsy core was significantly smaller, however, tumor volume and max% 
were significantly higher and more positive biopsy cores were presented than control. 
Worse pathological stage and more margin-positive were observed in group A and C 
than in control. Hazard ratio for biochemical failure was also higher in group A and C 
(P = 0.001). However, the groups were not independent factors in multivariate 
analysis. In conclusion, large difference between bGS and pGS shows poor prognosis 
even in the decreased group. However it is not an independent prognostic factor for 
biochemical failure. 
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ORIGINAL ARTICLE
Oncology & Hematology
INTRODUCTION
The prostate cancer is the most common malignant disease of 
men in Western countries (1). Its incidence is continuously in-
creasing Korea and its age-standardized incidence rates per 
100,000 men was 4.6 cases, which was the 8th-highest cause 
among the organ-specific malignant tumors in 2007 (2). Many 
pre-treatment prognostic factors have been proposed to be used 
to determine one of the treatment modalities and the Gleason 
system was proved to be one of the most important prognostic 
factors. Histological variation within each tumor brought two 
grades, the predominant, or primary grade and the less exten-
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sive, or secondary grade (3). Biopsy-derived Gleason score (bGS) 
is used as one of the most important pretreatment prognostic 
factors (4, 5). Though the overall accuracy of Gleason grade on 
needle biopsies was found to be good in predicting prostatec-
tomy specimen grade, upgrading and downgrading have been 
reported 9%-26% and 18%-22%, respectively (6, 7). Moreover, 
large difference (≥ 2 points) between biopsy-derived and post-
prostatectomy Gleason scores (pGS) may confuse the clinicians 
in consulting the patients. We investigated the clinical signifi-
cance of this difference.
 
MATERIALS AND METHODS
At 14 medical centers in Korea, the medical records of 1,582 men 
who underwent radical prostatectomy for prostate cancer be-
tween 1995 and 2007 were reviewed retrospectively. Prostate 
biopsy was recommended to the patients who had abnormal 
finding in digital rectal examination or whose serum prostate 
specific antigen (PSA) level was above 3.0 or 4.0 ng/mL accord-
ing to the policy for prostate biopsy of each medical center. All 
the pathologic slides of 18-gauge needle biopsy and the surgical 
prostate specimen from the involved medical centers were re-
evaluated by single expert uropathologist. According to the 2005 
International Society of Urological Pathology (ISUP) consensus 
on Gleason grading of prostatic carcinoma (8), bGS was defined 
as summation of primary GS and highest grade GS of all biopsy 
cores; and pGS was defined as summation of primary and sec-
ondary GS in the prostate specimen. Tumor volume was mea-
sured in the whole mount section of the resected prostate by the 
pathologist. The patients who took neoadjuvant therapy includ-
ing androgen deprivation or radiation therapy and the patients 
whose pathological slides showed too poor quality to reevalu-
ate were excluded. Finally 1,446 patients were included in this 
study. Biochemical failure was defined as serum PSA elevation 
above 0.2 ng/mL from nadir after radical prostatectomy. Time 
to biochemical failure was measured by the time interval from 
radical prostatectomy to biochemical failure. Needle biopsy 
specimen was taken from 6 (10.9%), 8 (8.4%), 10 (14.8%) and 12 
cores (65.8%) and additional cores of suspicious nodules. Clini-
cal stage was classified into cT1, cT2, and cT3 based on digital 
rectal examination and MRI findings. Operation procedure was 
included 1,036 radical retropubic prostatectomies (71.6%), 220 
radical perineal prostatectomies (15.2%), 125 laparoscopic rad-
ical prostatectomies (8.6%) and 65 robot-assisted radical pros-
tatectomies (4.5%). Mean age was 64.9 (38-85) yr old and pre-
operative sPSA was 11.8 ng/mL. The distribution of bGS was 
46.7%, 39.5% and 13.8% in GS ≤ 6, 7, and ≥ 8, respectively (Table 
1). According to the difference between bGS and pGS, the pa-
tients were divided into three groups: group A (decreased in pGS 
by 2 or more), group B as a control group (changed in pGS with-
in 1 point), and group C (increased in pGS by 2 or more). We 
evaluated various clinicopathological factors of prostate cancer, 
including age, preoperative sPSA, the number of biopsy cores, 
the highest cancer % in biopsy cores, clinical and pathological 
stage, volume % and distribution of cancer cells in surgical spec-
imen, and surgical margin status, univariately and multivari-
ately. Hazards for biochemical failure of these groups were also 
analyzed. 
 ANOVA and chi-square test was used for analysis of the vari-
ables in three groups. Scheffe’s method and Dunnett’s C meth-
od were used for post-hoc test for identifying the groups which 
made difference. Kaplan-Meier method and log rank test and 
Cox-regression hazard model were used for analysis of the haz-
ards for biochemical failure of the groups. 
Ethics statement
This study was reviewed and approved by the institutional re-
view board of the Samsung Medical Center (No. 2008-05-067). 
The board exempted informed consent because it was a retro-
spective study.
 
RESULTS
Each group included 30 (2.1%), 1,361 (94.1%) and 55 (3.8%) pa-
tients. Group A included bGS 7, 9 and 10 by 26.7%, 70.0%, and 
3.3%, respectively, and group C, bGS 4, 5, 6, 7, and 8 by 5.5%, 7.3%, 
21.8%, 63.6%, and 1.8% (Table 1). In the comparison of the clin-
icopathological factors of the three groups, the number of biop-
sy cores, maximal cancer % in positive cores, clinical and path-
ological stage, cancer volume %, and surgical margin status were 
significantly different (Table 2). In group A and C, maximal % of 
tumor in biopsy cores (P < 0.001 and P = 0.032, respectively) and 
margin positivity (P = 0.025 and P = 0.002, respectively) were 
higher than the control group B and pathological T stage was 
also worse in the group A and C than the control group B (P = 
0.006 and P < 0.001, respectively). In group C, the number of bi-
opsy core was significantly lower but tumor volume % in the pa-
thology specimen was significantly higher and tumor was more 
widely distributed in the prostate specimen than the control 
group B (P = 0.001), which were different aspects from group A 
Table 1. Proportion of the bGS in the three groups
Biopsy-derived  
   Gleason score
Group A (%) Group B (%) Group C (%)
  4 -     3 (0.2) 3 (5.5)
  5 -   15 (1.1) 4 (7.3)
  6 -   639 (47.0) 12 (21.8)
  7   8 (26.7)   528 (38.8) 35 (63.6)
  8 - 102 (7.5) 1 (1.8)
  9 21 (70.0)   69 (5.1) -
10 1 (3.3)     5 (0.4) -
Total 30 1,361 55
Group A (decreased in pGS by 2 or more), Group B (changed in pGS within 1 point), 
Group C (increased in pGS by 2 or more).
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(Table 3). Of the patients in group A, 73.3% diagnosed as prostate 
cancer of bGS 9 or 10 and their pGS fell into pGS 7 or 8. Though 
pGS of 8 patients (26.7%) who was diagnosed as bGS 7 was de-
creased to 5, the pathological stage of 7 of them were pT2c or 
higher. 
 Hazard ratio (HR) for biochemical failure was significantly 
higher in both groups (Group A, HR 2.385, 95% CI [1.222-4.656] 
P = 0.011; Group C, HR 1.750, 95% CI [1.147-2.672], P = 0.009) 
(Fig. 1). The median time to biochemical failure in group A and 
C were 46.0 and 62.6 months respectively but that of the control 
group did not reach median value within follow-up period. In 
multivariate analysis, however, this difference of bGS and pGS 
was not an independent prognostic factor of biochemical recur-
rence. Well-known prognostic factors of prostate cancer such as 
pGS (P = 0.045), pT stage (P < 0.001), surgical margin (P = 0.004) 
were significant in multivariate analysis (Table 4). 
 
Table 2. Comparison of the clinicopathological factors of the three groups
Parameters Group A Group B Group C P value
No. of the patients 30 1,361 55 -
Age (yr) 64.7 ± 7.0 64.9 ± 6.6 65.7 ± 5.9 0.653
Preoperative PSA (ng/dL) 11.4 ± 6.9   11.8 ± 15.4   15.1 ± 11.9 0.289
Body mass index (kg/m2) 24.5 ± 3.5 24.1 ± 3.3 24.1 ± 3.1 0.792
Prostate volume (mL)   36.5 ± 13.2   37.1 ± 17.9   32.8 ± 14.5 0.270
Clinical T stage (%)
   cT1
   cT2
   cT3
 
   14 (46.7)
   14 (46.7)
   2 (6.7)
 
  725 (53.5)
  515 (38.0)
114 (8.4)
 
24 (45.3)
23 (43.4)
  6 (11.3)
 
0.006
No. of biopsy core (%)
   ≤ 7
   8-10
   10-12
   ≥ 12
 
     4 (13.8)
   1 (3.4)
   1 (3.4)
   20 (67.0)
 
  140 (10.3)
116 (8.6)
  194 (14.3)
  903 (66.7)
 
13 (23.6)
4 (7.3)
15 (27.3)
23 (41.8)
 
0.002
Maximal % of tumor in biopsy cores   64.3 ± 23.1   41.8 ± 29.0   52.3 ± 34.1 < 0.001
Tumor volume % in prostate specimen   19.2 ± 18.1   15.1 ± 18.1   28.0 ± 23.4 < 0.001
Pathological T stage (%)
   pT2
   pT3a
   pT3b
   pT4
 
15 (50.0)
     7 (23.3)
     7 (23.3)
   1 (3.3)
 
  953 (70.1)
  280 (20.6)
102 (7.5)
  25 (1.8)
 
18 (33.3)
23 (42.6)
12 (22.2)
1 (1.9)
 
< 0.001
Tumor distribution (%)
   Apex
   Peripheral 
   Base
   Apex to base
 
     6 (24.0)
     6 (24.0)
     3 (12.0)
   10 (40.0)
 
  486 (38.2)
  327 (25.7)
  206 (16.2)
  253 (19.9)
 
  9 (20.0)
  9 (20.0)
  7 (15.6)
20 (44.4)
 
0.001
Margin positivity (%)
   Positive
   Margin free
 
15 (50)
15 (50)
 
  419 (30.8)
  942 (69.2)
 
28 (50.9)
27 (49.1)
 
0.001
Group A (decreased in pGS by 2 or more), Group B (changed in pGS within 1 point), Group C (increased in pGS by 2 or more).
Table 3. Difference of the variables of the group A and the group C compared with 
those of group B
Variables
P values
Group A Group C
No. of biopsy core 0.745 < 0.001
Maximal % of tumor in biopsy cores* < 0.001 0.032
Tumor volume % in pathology* 0.482 < 0.001
Pathological T stage 0.006 < 0.001
Tumor distribution 0.090 0.001
Margin positive rate 0.025 0.002
*by Scheffe’s method and Dunnett’s C method in post-hoc test. Group A (decreased 
in pGS by 2 or more), Group B (changed in pGS within 1 point), Group C (increased in 
pGS by 2 or more). 
Fig. 1. Hazard for biochemical recurrence of the three groups: Group A (decreased in 
pGS by 2 or more), Group B as a control group (changed in pGS within 1 point), and 
Group C (increased in pGS by 2 or more).
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Table 4. Multivariate analysis of the clinicopathological factors of prostate cancer and the difference groups of bGS and pGS
Variables HR 95% CI P value
Age 0.988 0.966-1.010 0.277
Preoperative serum PSA 1.005 1.000-1.010 0.061
Biopsy-derived Gleason score (compared with 2-6) 
   7
   8-10
 
1.439
2.038
 
0.967-2.140
1.143-3.634
0.051
Pathological Gleason score (compared with 2-6)
   7
   8-10
 
1.423
2.339
 
0.882-2.296
1.184-4.624
0.045
Clinical T stage (compared with cT1)
   cT2
   cT3
 
1.297
1.222
 
0.975-1.725
0.863-1.732
0.173
Pathological T stage (compared with cT2
   cT3
   cT4
 
2.109
1.945
 
1.533-2.902
0.952-3.975
< 0.001
Surgical margin (compared with cancer-free margin)
   Cancer involvement
 
1.538
 
1.145-2.065
0.004
Difference groups of bGS and pGS (compared with Group B)
   Group A
   Group C
 
1.437
0.883
 
0.664-3.111
0.475-1.640
0.644
bGS, biopsy-derived Gleason score; pGS, pathological Gleason score; Group A (decreased in pGS by 2 or more), Group B (changed in pGS within 1 point), and Group C (increased 
in pGS by 2 or more); HR, Hazard ratio; CI, Confidence interval.
DISCUSSION
It has been noted that there is 20%-40% of discrepancy between 
bGS and pGS in the pathology of prostate cancer (6, 7, 9). Inter-
estingly, in the univariate analysis, the result of current study 
demonstrated that the patients with this large difference be-
tween GS of pre- and post-prostatectomy showed worse clini-
copathological findings and worse prognosis in biochemical 
failure than the control group irrespective of increase or decrease 
of the pGS compared with bGS. A similar study to this, in which 
the patients were classified into three groups, namely, upgrad-
ed, downgraded, and unchanged, proposed that GS upgrading 
was associated with adverse pathological outcome compared 
with downgraded and unchanged groups, which included high-
er rates of extraprostatic extension, lymph node metastasis, pos-
itive surgical margins, and seminal vesicle invasion (7). Of the 
patients who showed two or more points decreased in pGS from 
bGS, 50% was diagnosed as pT3a or higher. Some of them were 
diagnosed as pGS 5, however, pathological stage of most of them 
was pT2c or higher. One of the reasons of this discrepancy be-
tween bGS and pGS may be sampling error in biopsy of hetero-
genic and multicentric prostate cancer (10). Prostate cancer 
which showed uniform pattern histology was reported only 12%-
33% in several studies (11). Another reason can be considered 
as the presence of high grade of tertiary component. Needle bi-
opsy specimen could be obtained mainly in high grade of ter-
tiary component, which would be ignored in prostatectomy 
specimen. If the biopsy specimen contained small amount of 
high grade prostate cancer, the pathologists would be tend to 
diagnose needle biopsy specimen as more aggressive cancer. In 
a study, analyzing 101 completely sectioned whole-mounted 
radical prostatectomy samples, the average number of different 
grades was 2.7 (range 1-5) (12). In an extended study with 155 
tumors from 61 whole-mounted radical prostatectomy samples, 
15% of tumors included three or more histological grades (13). 
A recent meta-analysis revealed that the presence of tertiary 
grade correlated with pathological stage, PSA recurrence and 
clinical progression (14). In several studies, samples character-
ized with pathological variables of poor outcome, such as extra-
prostatic extension and positive surgical margins contained a 
high grade tertiary component with consistently higher frequen-
cy (15, 16). Therefore bGS of the patients in group A rather than 
pGS may reflect prognosis and should be considered as one of 
the important prognostic factors together with pathological stage. 
 The patients who showed two or more points increase in pGS 
from bGS also demonstrated aggressive tumor burden and poor 
prognosis in biochemical failure. In these patients, the number 
of biopsy core was significantly smaller than other groups. A re-
cent study of 301 patients with low-risk prostate cancer (clinical 
Stage T1c-T2a, PSA ≤ 10 ng/mL, and bGS ≤ 6) who underwent 
an extended (≥ 10-core) prostate needle biopsy, in men assessed 
with 10-12 cores, the rate of GS upgrading was 47.9%, which was 
significantly higher than 23.5% in 18 cores (17). In another study, 
the authors proposed that prostate size and number of sampling 
was associated with Gleason upgrading (18). The mean pros-
tate volume of the patients in group C was smaller than that of 
control group. On the other hand, tumor volume in whole-mount 
prostate was bigger. Thus insufficient number of prostate sam-
pling, especially in small prostate containing aggressive cancer 
might cause Gleason upgrading. However, multivariate analysis 
showed clinical significance not in the difference of bGS and 
pGS but in well-known prognostic factors of prostate cancer 
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such as sPSA, bGS or pGS itself, pT stage and surgical margin. 
In the clinical settings, even if both of the clinicians and the pa-
tients would be confused with the somewhat large discrepancy 
in bGS and pGS, it can be ignored compared with other well-
known prognostic clinicopathological factors. However, the cli-
nicians had better kept in mind that many of these patients who 
showed large discrepancy in bGS and pGS might have other 
unfavorable clinicopathological factors of prostate cancer. 
 Bias related with interobserver variation in the pathologic re-
sult of Gleason score or Gleason sum would be one of major lim-
itation of this kind of study. A considerable interobserver varia-
tion in the Gleason scores of prostate cancer referred to several 
studies has been reported (19, 20). In addition, we did not review 
the tertiary component of prostate cancer specimen in group A, 
and survival analysis was not included due to the short follow-
up period. Practically, the large Gleason score gap of 2 or more 
points in bGS and pGS rarely occurs. In the current study, the 
total number of reviewed patients was 1,582, however, the num-
ber of focused patients was very small, which can be addressed 
as another limit point. 
 In summary, large difference between bGS and pGS shows 
poor prognosis even in the decreased group. However it is not 
an independent prognostic factor for biochemical failure.
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Large difference (≥ 2 points) between biopsy-derived (bGS) and post-prostatectomy Gleason scores (pGS) may confuse the 
clinicians in consulting the patients with prostate cancer. In the present study, we compared the prognosis of patients with the 
difference between pGS and bGS. When the pGS was changed from bGS by 2 points or above, such patients showed poor 
prognosis. Strikingly, even in the decreased group (pGS < bGS) showed poor prognosis. However the large difference between 
bGS and pGS was not an independent prognostic factor, and one should be cautious in the interpretation of the scoring values. 
